Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term extension study of litifilimab in adults with active systemic lupus erythematosus
MOH_2023-10-26_013014Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of litifilimab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Biogen. Started Oct 2023; status: active, not recruiting.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2023-10-26_013014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-26_013014.